Search

Context: Radiotherapy may have side effects on the brain, such as radiation necrosis, cognitive impairment, and a high chance of tumor recurrence, which has been considered the most common cause of treatment failure.Aims: Using intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) techniques, we aimed to test the potential outcome of sparing the contralateral hippocampus (CLH) in radiotherapy for brain tumors by comparing dosimetric parameters.Settings and Design: A prospective clinical comparative study.Subjects and Methods: Using IMRT and VMAT, sparing CLH in radiotherapy of brain tumors was tested in ten patients, and various dosimetric parameters were compared. The treatment plans were accepted only if they met the set of planning objectives defined in the protocol.Results: The dose delivered to 95% of the CLH volume (CLH D95), and the mean (CLH Dmean) and max (CLH Dmax) doses were found to be significantly highest in the standard IMRT (P = 0.002, <0.001, and < 0.001, respectively). The lowest CLH D95, CLH Dmean and CLH Dmax for the hippocampus were detected in sparing VMAT planning than in the other plans (P < 0.05). None of the post hoc comparisons for CLH D95 was different among any of the plans, whereas the mean dose to CLH was statistically different among all paired comparisons (P < 0.008). The maximum dose to CLH was also statistically different among all paired plans (P < 0.008), except the dose difference between standard VMAT and IMRT plans.Conclusions: Although VMAT planning is troublesome and time-consuming, the advantage of sparing the hippocampus is beneficial, preserving the hippocampus and cognitive functions during radiotherapy. [ABSTRACT FROM AUTHOR]

Copyright of Turkish Journal of Oncology / Türk Onkoloji Dergisi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Oncology / Türk Onkoloji Dergisi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Invasive lobular carcinoma is the second most common histological type of invasive breast carcinoma. Invasive lobular carcinoma usually occurs bilaterally. They are multicentric and aggressive tumors. ILC treatment is similar with that of Invasive ductal carsinom. It requires a multidisciplinary approach. Common sites of breast cancer metastasis include the lung, liver, brain, adrenal glands, bones, and lymphnodes. Gastrointestinal metastases are rare. The stomach is a common site of metastasis. Immunohistochemical analysis of biopsy specimens taken from metastatic sites are key in determining primary tumors. Treatment is standard like other metastatic breast cancers. We report on a case of invasive lobular breast cancer with gastric metastasis. [ABSTRACT FROM AUTHOR]

Objective: Breast cancer is the most common cancer in women. The incidence of bilateral breast cancer is 2%-11%. Synchronous bilateral breast cancer is uncommon (1%-2%). Bilateral breast cancer has worse prognosis than unilateral cancer. The aim of the retrospective study was to evaluate the incidence and demographic features of synchronous bilateral breast cancer patients in our hospital. Methods: We analyzed 266 breast cancer patients who were treated at our oncology department between January 2010 and December 2013. Five patients had synchronous bilateral breast cancer that was diagnosed at the same time. Results: We determined that five (1.87%) patients had synchronous bilateral breast cancer in this study. Of the five patients, one was a man and four were women. Median age was 53 years (40-64). Two patients were in premenopausal status. One patient revealed a positive family history of first-degree relatives. All of the patients had estrogen receptor positivity and invasive ductal carcinoma histopathology. Neoadjuvant chemotherapy was given to four patients. Only one metastatic patient had palliative chemotherapy. All patients had modified radical mastectomies and postoperative radiation therapy for bilateral breast cancer. Conclusion: Our clinical findings show a correlation with literature knowledge. Synchronous bilateral breast cancer is uncommon, and published data indicates worse prognosis. Hence, patients should be evaluated for the risk of contralateral breast cancer carefully at the same time of diagnosis. [ABSTRACT FROM AUTHOR]

Acantholytic squamous cell carcinoma is an uncommon variant of squamous cell carcinoma. Acantholytic squamous cell carcinoma occurs in the sun-exposed areas of the skin and lip. It is rarely observed in the respiratory and digestive tract and may present more aggressively. The incidence of distant metastases of squamous cell head and neck cancers is low and the lungs are the most common metastatic sites. Metastasis to the soft tissue, skin, and adrenal glands from the laryngeal region is very uncommon. In this article, we report a 58-year-old female case who underwent postoperative radiation therapy with the diagnosis of acantholytic squamous cell carcinoma of the larynx and developed metastasis to the soft tissue and adrenal gland at the early period.

Background: The aim of this study was to evaluate paraoxonase-1 (PON1) and arylesterase (ARE) activities and oxidative stress status in patients with colorectal carcinomas (CRC)., Materials and Methods: Thirty-three patients (20 male, 13 female) with CRC and 30 healthy controls were enrolled in the study. Blood samples were obtained from the CRC patients before adjuvant therapy. Serum samples from CRC patients and healthy controls were analyzed for PON1 and ARE activities., Results: The PON1 and ARE activities of the patients with CRC were significantly higher compared to those of the control group (PON1 activity is 125.35±20.07 U/L for CRC patients and 1.22±0.48 U/L for control group, P<0.001; ARE activity is 160.76±10.79 U/L for CRC patients). ARE levels showed a positive correlation with smoking status (P=0.04). PON1 activity was higher in colon carcinoma patients (135.95±19.3 U/L) rather than rectal carcinoma patients (97.08±5.24 U/L) but it was not statistically significant (P=0.72)., Conclusion: Serum PON1 activity is increased in patients with CRC, and serum ARE levels showed a positive correlation with smoking status. PON1 activity was higher in colon carcinoma patients. There is no other study in literature investigating these activities for CRC patients. It should be reevaluated by larger clinical trials.